Technology | November 16, 2012

FDA Clears First Forward-Looking Imaging Catheter to Treat Chronic Total Occlusions

Avinger’s Ocelot System use optical coherenace tomography (OCT) to better navigate occluded peripheral vessels

Avinger Ocelot OCT CTO catheter

November 16, 2012 – The U.S. Food and Drug Administration (FDA) has granted market clearance for the Avinger Inc. Ocelot optical coherenace tomography (OCT) catheter to help cross chronic total occlusions (CTOs) in patients with peripheral artery disease (PAD).

The Ocelot catheter, supported by the Lightbox console, allows physicians to see from inside an artery during the actual procedure using forward-looking OCT. In the past, operators have had to rely solely on X-ray angiography and touch to guide catheters through complicated blockages. The current method makes for imprecise vessel navigation, leading to long procedure times and possible complications, such as vessel perforation. With Ocelot, physicians can more accurately navigate through CTOs thanks to the addition of imaging what is ahead of the catheter.

Avinger successfully completed enrollment in its CONNECT II global clinical trial in June 2012. The Ocelot System demonstrated a CTO crossing success of 97 percent with a 98 percent freedom from major adverse events (MAEs).  

“It has taken my entire career to get to this moment,” said John B. Simpson Ph.D., M.D., Avinger founder and CEO. “Incorporating intravascular OCT into therapeutic devices has been the biggest priority here at Avinger. We have amazing investors who have allowed us to demonstrate how revolutionary Avinger can be. I’m so proud of our employees, all the physicians and hospitals around the world that helped us bring this amazing technology to the patients in the U.S.”

PAD is an unrecognized epidemic that affects between eight and 12 million adults in the United States and 30 million people globally. It is caused by a build-up of plaque in the arteries that blocks blood flow to the legs and feet. “Often times, bypass surgeries or amputations are the recommended solutions. Ocelot can help save patients from such dire circumstances and patients can be back on their feet in days,” continued Dr. Simpson.

A total of 122 patients from both Europe and the U.S. took part in the Ocelot global clinical trial, the results of which led to today’s FDA clearance.

Often dismissed as normal signs of aging, symptoms of PAD include painful cramping, numbness, or discoloration in the legs or feet. Hospitalization costs of PAD alone are estimated to exceed $21 billion annually, largely due to late detection and patients experiencing a decreased quality of life from invasive bypass surgery or amputation.  

Because some blockages can become so severe and difficult to penetrate with traditional catheters, patients often are subjected to extremely invasive bypass surgeries that result in even higher health risks and lengthy, painful recoveries. 

For more information: www.avinger.com

 

 

Related Content

Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
Videos | Cath Lab | September 14, 2018
A discussion with Nicolas Bevins, Ph.D., vice chair, physics and research, and Jessica Harrington, RCIS.
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology cath lab Market.
Feature | Cath Lab | May 07, 2018 | Simon Trinh and Jeffrey Wong
The European interventional cardiology market is currently valued at nearly $1.4 billion.
Overlay Init